Pfizer’s new COVID-19 vaccine approved, Health Canada says

Pfizer-BioNTech’s latest vaccine to protect against newly circulating COVID-19 variants has been authorized, Health Canada said Tuesday.

The federal vaccines and treatments portal lists Comirnaty’s product authorization, stating it includes an updated composition to target the KP.2 subvariant from Omicron.

Pfizer said the newly formulated vaccine will be available at pharmacies and vaccination centers across the country “in the fall.” The company urged people to contact provincial and territorial authorities about how to access it.

Last week, Health Canada approved another mRNA vaccine, Moderna’s Spikevax, as well as a protein-based vaccine from Novavax, called Nuvaxovid.

WATCH | Addressing the long-term health impacts of COVID-19:

Experts now say the impact of COVID-19 goes far beyond the initial illness

Early research suggests an alarming percentage of recovered COVID-19 patients have a chronic respiratory condition called pulmonary fibrosis.

Pfizer’s previous vaccine targeted an earlier Omicron subvariant called XBB.1.5.

The new Pfizer and Moderna vaccines are approved for adults and children six months and older.

Novavax is approved for adults and those 12 years and older.